CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively modulate disease-relevant T cells. Headquartered in Boston, Massachusetts, the company's Immuno-STAT platform is designed to harness the body's immune system to fight cancer and autoimmune diseases. Cue Biopharma's lead programs target various cancers including HPV-driven malignancies and other solid tumors. The company's approach aims to deliver more targeted immunotherapy with improved efficacy and reduced side effects compared to traditional treatments.